title: Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001.
abstract: OBJECTIVE
  To evaluate the longitudinal development of the tricuspid gradient (TG) for screening for pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc).
  
  
  METHODS
  Doppler echocardiography was performed 506 times in order to estimate TG in 227 consecutive patients with SSc. The value of biochemical markers for predicting TG levels and development was assessed through analyses of pro-brain natriuretic peptide (proBNP), calcitonin-gene related peptide, thrombomodulin and von Willebrand factor in 76 patients with a borderline increase in TG, defined as TG 24-38 mmHg, and for the purpose of comparison also in 10 patients with a normal TG (< 23 mmHg) and in 10 patients with increased TG (TG > 38 mmHg).
  
  
  RESULTS
  TG > 23 mmHg was found in 102 patients (44.9%) at the first assessment point and in 139 patients (61.2%) respectively, cumulatively at follow-up. TG values > 33 mmHg were measured in 24 patients (10.6%) initially and in 38 patients (16.7%) cumulatively in a subsequent assessment. Age and the presence of interstitial lung disease (ILD) were associated with more frequent occurrence of TG > 23 and > 33 mmHg initially and at follow-up, but were not associated with progression rate. The change in TG (mean +/- S.D.) was 1.34 +/- 4.55 mmHg/yr. ProBNP correlated to TG.
  
  
  CONCLUSIONS
  An increased TG, indicating possible PAH, is common and progressive in SSc. Age and ILD increase the risk of increased TG. Patients with or without ILD have similar progression of TG. ProBNP has potential as an adjunct to TG in selecting patients eligible for invasive treatment.
authors.affiliation: Department of Rheumatology, Lund University Hospital, Lund, Sweden. roger.hesselstrand@skane.se
authors.forename: R
authors.initials: R
authors.lastname: Hesselstrand
authors.forename: R
authors.initials: R
authors.lastname: Ekman
authors.forename: J
authors.initials: J
authors.lastname: Eskilsson
authors.forename: A
authors.initials: A
authors.lastname: Isaksson
authors.forename: A
authors.initials: A
authors.lastname: Scheja
authors.forename: A-K
authors.initials: AK
authors.lastname: Ohlin
authors.forename: A
authors.initials: A
authors.lastname: Akesson
mesh_terms: D000367:Age Factors; D001794:Blood Pressure; D015740:Calcitonin Gene-Related Peptide / Q000032:analysis; D002248:Carbon Monoxide / Q000502:physiology; D015150:Echocardiography, Doppler / Q000379:methods; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications / Q000000981:diagnostic imaging* / Q000503:physiopathology; D017563:Lung Diseases, Interstitial / Q000150:complications / Q000503:physiopathology; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000032:analysis; D012595:Scleroderma, Systemic / Q000150:complications* / Q000000981:diagnostic imaging / Q000503:physiopathology; D018180:Thrombomodulin / Q000032:analysis; D014261:Tricuspid Valve / Q000000981:diagnostic imaging / Q000503:physiopathology*; D014262:Tricuspid Valve Insufficiency / Q000150:complications / Q000000981:diagnostic imaging / Q000503:physiopathology; D014841:von Willebrand Factor / Q000032:analysis
chemical_list: D018180:Thrombomodulin; D014841:von Willebrand Factor; D020097:Natriuretic Peptide, Brain; D002248:Carbon Monoxide; D015740:Calcitonin Gene-Related Peptide